Free Access
Med Sci (Paris)
Volume 21, Number 1, Janvier 2005
Page(s) 73 - 77
Section M/S Revues
Published online 15 January 2005
  1. Tokunaga T, Yamamoto H, Shimada S, et al. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J Natl Cancer Inst 1984; 72 : 955–62. [Google Scholar]
  2. Krieg AM, Yi AK, Matson S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374 : 546–9. [Google Scholar]
  3. Yamamoto S, Yamamoto T, Kataoka T, et al. Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN and augment IFN-mediated natural killer activity. J Immunol 1992; 148 : 4072–6. [Google Scholar]
  4. Hacker H. Signal transduction pathways activated by CpG-DNA. Curr Top Microbiol Immunol 2000; 247 : 77–92. [Google Scholar]
  5. Hemmi H, Takeuchi O, Kawai T, et al. Toll-like receptor recognizes bacterial DNA. Nature 2000; 408 : 740–5. [Google Scholar]
  6. Takeshita F, Leifer CA, Gursel I, et al. Cutting edge : role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J Immunol 2001; 167 : 3555–8. [Google Scholar]
  7. Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 2004; 4 : 249–59. [Google Scholar]
  8. Hornung V, Rothenfusser S, Britsch S, et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002; 168 : 4531–7. [Google Scholar]
  9. Carpentier AF, Auf G, Delattre JY. CpG-oligonucleotides for cancer immunotherapy : review of the literature and potential applications in malignant glioma. Front Biosci 2003; 8 : E115–27. [Google Scholar]
  10. Jung J, Yi AK, Zhang X, et al. Distinct response of human B cell subpopulations in recognition of an innate immune signal, CpG DNA. J Immunol 2002; 169 : 2368–73. [Google Scholar]
  11. Sparwasser T, Koch ES, Vabulas RM, et al. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol 1998; 28 : 2045–54. [Google Scholar]
  12. Ban E, Dupre L, Hermann E, et al. CpG motifs induce Langerhans cell migration in vivo. Int Immunol 2000; 12 : 737–45. [Google Scholar]
  13. Krug A, Towarowski A, Britsch S, et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol 2001; 31 : 3026–37. [Google Scholar]
  14. Kline JN, Waldschmidt TJ, Businga TR, et al. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J Immunol 1998; 160 : 2555–9. [Google Scholar]
  15. Cho HJ, Takabayashi K, Cheng PM, et al. Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism. Nat Biotechnol 2000; 18 : 509–14. [Google Scholar]
  16. Krieg AM. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr Oncol Rep 2004; 6 : 88–95. [Google Scholar]
  17. Hartmann G, Weeratna RD, Ballas ZK, et al. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol 2000; 164 : 1617–24. [Google Scholar]
  18. Carpentier AF, Chen L, Maltonti F, Delattre JY. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res 1999; 59 : 5429–32. [Google Scholar]
  19. Carpentier AF, Xie J, Mokhtari K, Delattre JY. Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin Cancer Res 2000; 6 : 2469–73. [Google Scholar]
  20. Decker T, Schneller F, Sparwasser T, et al. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood 2000; 95 : 999–1006. [Google Scholar]
  21. Hafner M, Zawatzky R, Hirtreiter C, et al. Antimetastatic effect of CpG DNA mediated by type I IFN. Cancer Res 2001; 61 : 5523–8. [Google Scholar]
  22. Lanuti M, Rudginsky S, Force SD, et al. Cationic lipid/bacterial DNA complexes elicit adaptive cellular immunity in murine intraperitoneal tumor models. Cancer Res 2000; 60 : 2955–63. [Google Scholar]
  23. Kawarada Y, Ganss R, Garbi N, et al. NK- and CD8+ T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J Immunol 2001; 167 : 5247–53 [Google Scholar]
  24. Hartmann E, Wollenberg B, Rothenfusser S, et al. Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res 2003; 63 : 6478–87. [Google Scholar]
  25. Vicari AP, Chiodoni C, Vaure C, et al. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J Exp Med 2002; 196 : 541–9. [Google Scholar]
  26. Trefzer U, Kors C, Pelzer K, et al. Preliminary results of a phase I trial of intralesional injection of CpG-DNA in basal cell carcinoma and melanoma. 2nd International Symposium Activating immunity with CpG Oligos. Amelia Island, Florida, 7-10 octobre 2001. [Google Scholar]
  27. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002; 20 : 709–60. [Google Scholar]
  28. Zwaveling S, Ferreira Mota SC, Nouta J, et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 2002; 169 : 350–8. [Google Scholar]
  29. Miconnet I, Koenig S, Speiser D, et al. CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. J Immunol 2002; 68 : 1212–8. [Google Scholar]
  30. Davila E , Celis E. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity. J Immunol 2000; 165 : 539–47. [Google Scholar]
  31. Tighe H, Takabayashi K, Schwartz D, et al. Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol 2000; 106 : 124–34. [Google Scholar]
  32. Kim SK, Ragupathi G, Cappello S, et al. Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates. Vaccine 2000; 19 : 530–7. [Google Scholar]
  33. Liu HM, Newbrough SE, Bhatia SK, et al. Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor. Blood 1998; 92 : 3730–6. [Google Scholar]
  34. Warren TL, Dahle CE, GJ Weiner. CpG oligodeoxynucleotides enhance monoclonal antibody therapy of a murine lymphoma. Clin Lymphoma 2000; 1 : 57–61. [Google Scholar]
  35. Decker T, Hipp S, Kreitman RJ, et al. Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides. Blood 2002; 99 : 1320–6. [Google Scholar]
  36. Egeter OR, Mocikat K, Ghoreschi A, et al. Eradication of disseminated lymphomas with CpG-DNA activated T helper type 1 cells from nontransgenic mice. Cancer Res 2000; 60 : 1515–20. [Google Scholar]
  37. Heckelsmiller K, Beck S, Rall K, et al. Combined dendritic cell and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy. Eur J Immunol 2002; 32 : 3235–45. [Google Scholar]
  38. Weigel BJ, Rodeberg DA, Krieg AM, Blazar BR. CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin Cancer Res 2003; 9 : 3105–14. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.